A PHASE II STUDY OF VORINOSTAT (MK-0683) IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF) AND POST-POLYCYTHAEMIA VERA MYELOFIBROSIS (PPV-MF)

被引：0
|
作者：
Andersen, C. [1 ]
Mortensen, N. [1 ]
Vestergaard, H. [2 ]
Bjerrum, O. [3 ]
Klausen, T. [4 ]
Hasselbalch, H. [1 ]
机构：
[1] Roskilde Univ Hosp, Dept Haematol, Roskilde, Denmark
[2] Odense Univ Hosp, Dept Haematol, Odense, Denmark
[3] Copenhagen Univ Hosp, Dept Haematol, Copenhagen, Denmark
[4] Herlev Hosp, Dept Haematol, Herlev, Denmark
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P279
引用
收藏
页码：120 / 120
页数：1
相关论文
共 50 条
  • [31] An open-label, multicenter, expanded access study assessing the safety and efficacy of oral ruxolitinib administered to patients with primary myelofibrosis (PMF), post-polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF).
    le Coutre, Philipp D.
    Gisslinger, Heinz
    Zachee, Pierre
    Gupta, Vikas
    Perez, Jose Ricardo
    Schenk, Nora
    Vutukuru, Suresh
    Garcia-Hernandez, Carmen
    Tavares, Renato
    Bocchia, Monica
    Niederwieser, Dietger
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] Array-Based Comparative Genomic Hybridization (aCGH) In Myelofibrosis Reveals Divergent Genetic Copy Number Alterations Among Patients With Post-Essential Thrombocythemia-Myelofibrosis/Post-Polycythemia Rubra Vera-Myelofibrosis (PET-MF and PPV-MF) and Patients With Idiopathic Myelofibrosis
    Savona, Michael
    Ma, Zeqiang
    DeBusk, Laura
    Chandra, Pranil
    Liang, Shile
    Cooper, R. Seth
    Raefsky, Eric
    Gian, Victor
    Hockett, Richard
    Berdeja, Jesus
    Lennon, P. Alan
    BLOOD, 2013, 122 (21)
  • [33] A Phase II Trial of Panobinostat, an Orally Available Deacetylase Inhibitor (DACi), in Patients with Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET), and Post Polycythemia Vera (PV) Myelofibrosis
    DeAngelo, Daniel J.
    Tefferi, Ayalew
    Fiskus, Warren
    Mesa, Ruben A.
    Paley, Carole S.
    Wadleigh, Martha
    Snyder, David S.
    Begna, Kebede
    Ondovik, Michael S.
    Rine, Jessica
    Bhalla, Kapil N.
    BLOOD, 2010, 116 (21) : 276 - 277
  • [34] Interim Analysis of a Phase II Pilot Trial of Ruxolitinib Combined with Danazol for Patients with Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET), and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering from Anemia
    Gowin, Krisstina L.
    Dueck, Amylou C.
    Mascarenhas, John O.
    Hoffman, Ronald
    Reeder, Craig B.
    Camoriano, John
    Gano, Katherine
    Ghurye, Vineta
    Reddy, Sravan Nagi
    Koenig, Patricia
    Fauble, Veena
    Tibes, Raoul
    Mesa, Ruben
    BLOOD, 2014, 124 (21)
  • [35] A Multicenter, Open-Label, Phase 1 Clinical Trial of AJ1-11095 Administered As Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed By a Type I JAK2 Inhibitor (JAK2i)
    Mascarenhas, John O.
    Borate, Uma
    Bose, Prithviraj
    Byrd, John C.
    Garcia, Jacqueline S.
    Grunwald, Michael R.
    Hobbs, Gabriela S.
    Hoffman, Ronald
    Kuykendall, Andrew T.
    Mesa, Ruben A.
    Oh, Stephen
    Rampal, Raajit
    Yacoub, Abdulraheem
    Steensma, David P.
    BLOOD, 2024, 144 : 31471 - 31473
  • [36] A phase II trial of oral panobinostat (LBH589), a no deacetylase inhibitor (DACi) in patients with primary myelofibrosis (PMF), post-essential thrombocythemia (ET) myelofibrosis, and post-polycythemia vera (PV) myelofibrosis
    DeAngelo, D. J.
    Tefferi, A.
    Mesa, R. A.
    Paley, C. S.
    Wadleigh, M.
    Snyder, D.
    Ondovik, M. S.
    Rine, J.
    Bhalla, K. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] Phase II Study of Sunitinib in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
    Apostolidou, Effrosyni
    Kantarjian, Hagop
    Thomas, Deborah
    Burger, Ian
    Borthakur, Gautam
    Verstovsek, Srdan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (04): : 281 - 284
  • [38] THE SELECTIVE JANUS KINASE (JAK) INHIBITOR, INCB018424, SHOWS EFFICACY IN A PHASE I/II TRIAL IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF) AND POST POLYCYTHEMIA VERA/ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-PV/ET MF)
    Verstovsek, S.
    Kantarjian, H.
    Pardanani, A.
    Thomas, D.
    Cortes, J.
    Mesa, R.
    Hogan, W.
    Redman, J.
    Levy, R.
    Vaddi, K.
    Fridman, J.
    Tefferi, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 179 - 179
  • [39] INCB018424, an oral, selective JAK2 inhibitor, shows significant clinical activity in a phase I/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera/essenlial thrombocythemia myelofibrosis (Post-PV/ET MF)
    Verstovsek, Srdan
    Kantarjian, Hagop
    Pardanani, Animesh
    Thomas, Deborah
    Cortes, Jorge
    Mesa, Ruben
    Redman, John
    Staschen, Carl-Michael
    Fridman, Jordan
    Vaddi, Kris
    Tefferi, Ayalew
    BLOOD, 2007, 110 (11) : 171A - 171A
  • [40] A phase II study of azacitidine (Vidaza™) for patients with myelofibrosis (MF).
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Thomas, Deborah
    Kornblau, Steven
    Estey, Elihu
    Nemri, Marilyn
    Cortes, Jorge
    Giles, Francis
    Verstovsek, Srdan
    BLOOD, 2006, 108 (11) : 765A - 765A
12345